Frontlight ResearchEarly access
CompletedNo phase
Autologous Bone Marrow Aspirate Concentrate Injection for the Treatment of Early Osteoarthritis:Baghdad 2022
Key facts
- Who runs it
- Global Stem Cell Center, Baghdad
- Where
- Iraq1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 8 Feb 2022
- Ended
- 16 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- autologous bone marrow aspirate concentrate by centrifugation
- Record updated
- 17 January 2024
Who can take part
- Age
- 55 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Radiological diagnosis of Osteoarthritis according to Kellgren and Lawrence Criteria stage II-III; Radiological grading of osteoarthritis of the knee determined by qualified radiologist using MOAKS scoring system; Primary osteoarthritis not responsive to conventional treatment and physiotherapy; A minimum pain score of 5 on an 11-point numerical scale; Age >55 years
Who cannot take part
- Previous knee surgery within the last 12 months
- Previous intra-articular injectable therapies within the last 6 months
- Knee symptom due to other condition like tumor or referred pain from lumbar spine
- History of severe systemic illness
- Active neoplasm under treatment in the last 12 months- Health conditions including known allergy to local
- Bleeding tendency
- Pregnancy and breast feeding
- MRI confirmed displaced meniscal tear
- MRI confirmed Grade IV chondral loss
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
We present a randomized controlled trial (RCT) to assess the efficacy of autologous bone marrow aspirate concentrate BMAC of 1.8x 10 9 median cellular content in the treatment of early symptomatic knee OA. We use 2 injections 2 months apart (8).
The 2 groups in the trial
- treatment with autologous bone marrow aspirate concentrateExisting treatment, for comparison
autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint
Treatment: autologous bone marrow aspirate concentrate by centrifugation
- controlSham treatment, for comparison
control group given analgesics only
Treatment: autologous bone marrow aspirate concentrate by centrifugation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autologous Bone Marrow Aspirate Concentrate Injection for the Treatment of Early Osteoarthritis: a Randomized Controlled Trial, Ibn-Sina Hospital, Baghdad 2022
- Record updated
- 17 January 2024